Argent BioPharma Limited (ASX:RGT)

Market Cap	4.00M -51.8%
Revenue (ttm)	347.78K +17.6%
Net Income	-8.62M
EPS	-0.12
Shares Out	111.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,590
Open	0.0380
Previous Close	0.0360
Day's Range	0.0340 - 0.0380
52-Week Range	0.0330 - 0.3200
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 11, 2026

About Argent BioPharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer’s. It i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RGT

Financial Performance

In fiscal year 2025, Argent BioPharma's revenue was 180,565, a decrease of -79.74% compared to the previous year's 891,083. Losses were -17.84 million, 1.79% more than in 2024.